-
1
-
-
44649098307
-
Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology foundation
-
J.D. Brunzell, M. Davidson, C.D. Furberg, R.B. Goldberg, B.V. Howard, J.H. Stein, J.L. Witztum Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology foundation Diabetes Care 31 2008 811 822
-
(2008)
Diabetes Care
, vol.31
, pp. 811-822
-
-
Brunzell, J.D.1
Davidson, M.2
Furberg, C.D.3
Goldberg, R.B.4
Howard, B.V.5
Stein, J.H.6
Witztum, J.L.7
-
2
-
-
34247478090
-
State of diabetes care in the United States
-
L. Blonde State of diabetes care in the United States Am J Manag Care 13 suppl 2007 S36 S40
-
(2007)
Am J Manag Care
, vol.13
, Issue.SUPPL.
-
-
Blonde, L.1
-
3
-
-
0037126526
-
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final report
-
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report Circulation 106 2002 3143 3421
-
(2002)
Circulation
, vol.106
, pp. 3143-3421
-
-
-
4
-
-
61349099439
-
Diagnosis and classification of diabetes mellitus (position statement)
-
American Diabetes Association
-
American Diabetes Association Diagnosis and classification of diabetes mellitus (position statement) Diabetes Care 32 2009 S62 S67
-
(2009)
Diabetes Care
, vol.32
-
-
-
5
-
-
0037840242
-
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomized placebo-controlled trial
-
Heart Protection Study Collaborative Group
-
Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial Lancet 361 2003 2005 2016
-
(2003)
Lancet
, vol.361
, pp. 2005-2016
-
-
-
6
-
-
33750804460
-
Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy
-
E. Jeyarajah, W. Cromwell, J. Otvos Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy Clin Lab Med 26 2006 847 870
-
(2006)
Clin Lab Med
, vol.26
, pp. 847-870
-
-
Jeyarajah, E.1
Cromwell, W.2
Otvos, J.3
-
7
-
-
0015348189
-
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
-
W.T. Friedewald, R.I. Levy, D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
-
(1972)
Clin Chem
, vol.18
, pp. 499-502
-
-
Friedewald, W.T.1
Levy, R.I.2
Fredrickson, D.S.3
-
8
-
-
79952515201
-
Clinical implications of discordance between low-density lipoprotein cholesterol and particle number
-
J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, D.C. Goff Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
-
(2011)
J Clin Lipidol
, vol.5
, pp. 105-113
-
-
Otvos, J.D.1
Mora, S.2
Shalaurova, I.3
Greenland, P.4
MacKey, R.H.5
Goff, D.C.6
-
9
-
-
2542461241
-
Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal
-
J.H. O'Keefe, L. Cordain, W.H. Harris, R.M. Moe, R. Vogel Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal J Am Call Cardiol 43 2004 2142 2146
-
(2004)
J Am Call Cardiol
, vol.43
, pp. 2142-2146
-
-
O'Keefe, J.H.1
Cordain, L.2
Harris, W.H.3
Moe, R.M.4
Vogel, R.5
-
10
-
-
35048833627
-
LDL particle number is highly heterogeneous among patients with type 2 diabetes at an LDL cholesterol target goal <100 mg/dl
-
W.C. Cromwell, J.D. Otvos LDL particle number is highly heterogeneous among patients with type 2 diabetes at an LDL cholesterol target goal <100 mg/dl Am J Cardiol 98 2006 1599 1602
-
(2006)
Am J Cardiol
, vol.98
, pp. 1599-1602
-
-
Cromwell, W.C.1
Otvos, J.D.2
-
11
-
-
36749101948
-
LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - Implications for LDL management
-
W.C. Cromwell, J.D. Otvos, M. Keyes, M. Pencina, L. Sullivan, R. Vasan, P. Wilson, R. D'Agostino LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management J Clin Lipidol 1 2007 583 592
-
(2007)
J Clin Lipidol
, vol.1
, pp. 583-592
-
-
Cromwell, W.C.1
Otvos, J.D.2
Keyes, M.3
Pencina, M.4
Sullivan, L.5
Vasan, R.6
Wilson, P.7
D'Agostino, R.8
-
12
-
-
80053914425
-
Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
-
M.H. Davidson, C.M. Ballantyne, T.A. Jacobson, V.A. Bittner, L.T. Braun, A.S. Brown, W.V. Brown, W. Cromwell, R.B. Goldberg, J.M. McKenney, A.T. Remaley, A.D. Sniderman, P.P. Toth, S. Tsimikas, P.E. Ziajka Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists J Clin Lipidol 5 2011 338 367
-
(2011)
J Clin Lipidol
, vol.5
, pp. 338-367
-
-
Davidson, M.H.1
Ballantyne, C.M.2
Jacobson, T.A.3
Bittner, V.A.4
Braun, L.T.5
Brown, A.S.6
Brown, W.V.7
Cromwell, W.8
Goldberg, R.B.9
McKenney, J.M.10
Remaley, A.T.11
Sniderman, A.D.12
Toth, P.P.13
Tsimikas, S.14
Ziajka, P.E.15
-
13
-
-
84864929338
-
-
Prevent CVD Publishing Madison, Wisconsin
-
R. Gleeson, M. Davidson Lipidology a Primer: The What, Why, and How of Better Lipid Management 2010 Prevent CVD Publishing Madison, Wisconsin 15 29
-
(2010)
Lipidology A Primer: The What, Why, and How of Better Lipid Management
, pp. 15-29
-
-
Gleeson, R.1
Davidson, M.2
|